Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA)
Dang C, Lin N, Lake D, Dickler M, Modi S, Seidman A, Steingart R, Norton L, Winer E, Hudis C. Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA). Journal Of Clinical Oncology 2008, 26: 518-518. DOI: 10.1200/jco.2008.26.15_suppl.518.Peer-Reviewed Original Research